<DOC>
	<DOCNO>NCT01843387</DOCNO>
	<brief_summary>The study investigate safety , tolerability efficacy single intravenous infusion two dos mesenchymal precursor cell versus placebo subject diabetic nephropathy type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Mesenchymal Precursor Cells Diabetic Nephropathy</brief_title>
	<detailed_description>This study take place Melbourne , Australia .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Men woman ≥ 50 ≤ 85 year old Subjects diagnose type 2 diabetes least 2 year prior Screening Subjects diabetic nephropathy CKD stage 3b4 Albumintocreatinine ratio ( ACR ) spot urine sample &gt; 30 &lt; 3000 mg/g Screening Subjects must receive standard care treatment diabetic nephropathy angiotensin convert enzyme inhibitor ( ACEi ) and/or angiotensin II receptor blocker ( ARB ) least 12 week prior Screening . HbA1c &lt; 10.0 % Screening Prior participation stem cell study Women childbearing potential Potentially unreliable subject judge Investigator unsuitable study History active substance abuse ( include alcohol ) within past 2 year . Current alcohol abuse define daily consumption &gt; 3 alcoholic beverage ( i.e . &gt; 21 alcoholic beverage per week ) Body weight &gt; 150 kg Subjects nondiabetic renal disease e.g . know polycystic kidney disease Subjects history renal transplant prior dialysis within 3 month Screening and/or maintain stable level kidney function within 3 month Screening Current history within 6 month Screening NYHA Class III IV heart failure Myocardial infarction stroke within 6 month prior Screening Any concurrent medical condition/disorder clinically symptomatic cardiovascular , gastrointestinal , hematological , pulmonary , acute chronic infectious disease , active retinal disease disorder Investigator 's opinion would interfere subject ability complete trial , would require administration treatment could affect interpretation efficacy safety variable would preclude safe involvement study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Metabolic disease</keyword>
	<keyword>Diabetes mellitus , type 2</keyword>
</DOC>